An Intriguing Approach to Slow Alzheimer’s Shows Mixed Results

1 hour ago 4

Well|An Intriguing Approach to Slow Alzheimer’s Shows Mixed Results

https://www.nytimes.com/2026/11/16/well/cognito-spectris-alzheimers-headset-device.html

You person a preview presumption of this nonfiction portion we are checking your access. When we person confirmed access, the afloat nonfiction contented volition load.

The device, a headset delivering airy and sound, is based connected the mentation that audiovisual stimulation tin evoke brainwave responses that mightiness assistance sphere neurological function.

A balding elder  antheral   seen from down  looks toward an out-of-frame window.
Credit...Arman Zhenikeyev/Getty Images

Pam Belluck

Nov. 16, 2026Updated 6:19 p.m. ET

The largest proceedings to day of a headset instrumentality that delivers flickering airy and dependable successful an effort to dilatory the progression of Alzheimer’s has delivered mixed results.

The instrumentality is based connected the mentation that audiovisual stimulation tin evoke brainwave responses that mightiness assistance sphere neurological relation and wide discarded from the brain. The thought is appealing because, if specified a attraction works, it could supply an accessible non-drug alternate to Alzheimer’s medications that are costly and transportation important information risks.

Results of the survey of the device, presented connected Monday evening astatine a large Alzheimer’s conference, showed that the 12-month proceedings involving participants with mild to mean Alzheimer’s did not execute its superior goal. The wide radical of patients who utilized the audiovisual instrumentality did not acquisition slower cognitive diminution than those who utilized an inactive placebo instrumentality called a sham.

Patients with mean Alzheimer’s showed nary payment astatine each from the system, called Spectris, according to information provided by the company, Cognito Therapeutics, which sponsored the trial. But for patients with mild Alzheimer’s, information mostly suggested they could acquisition slower diminution with the device, peculiarly if they utilized it astir each time for adjacent to the recommended 60 minutes.

Based connected that, Cognito’s main executive, Christian Howell, said the institution planned to question Food and Drug Administration approval.

“The awesome we recovered successful the mild colonisation is truly incredible,” Mr. Howell said successful an interview. He attributed the trial’s nonaccomplishment to conscionable its superior extremity to “the deficiency of attraction effect” successful patients with mean Alzheimer’s, but said that for mildly impaired patients, “there is simply a precise wide way for america to the F.D.A.”


Thank you for your patience portion we verify access. If you are successful Reader mode delight exit and log into your Times account, or subscribe for each of The Times.


Thank you for your patience portion we verify access.

Already a subscriber? Log in.

Want each of The Times? Subscribe.

Read Entire Article